Atala Financial Inc Purchases Shares of 246 IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Atala Financial Inc purchased a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 246 shares of the company’s stock, valued at approximately $102,000.

Several other hedge funds also recently added to or reduced their stakes in IDXX. FSA Wealth Management LLC purchased a new stake in IDEXX Laboratories in the third quarter valued at $25,000. Rialto Wealth Management LLC purchased a new stake in shares of IDEXX Laboratories during the 4th quarter worth about $30,000. Retirement Wealth Solutions LLC purchased a new stake in shares of IDEXX Laboratories during the 4th quarter worth about $31,000. Kestra Investment Management LLC purchased a new stake in shares of IDEXX Laboratories during the 4th quarter worth about $38,000. Finally, Crews Bank & Trust purchased a new stake in shares of IDEXX Laboratories during the 4th quarter worth about $41,000. 87.84% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

IDXX has been the topic of several recent analyst reports. Morgan Stanley lowered their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 29th. Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Leerink Partners initiated coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They set an “outperform” rating and a $500.00 target price on the stock. StockNews.com lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Barclays upped their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 4th. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and an average price target of $533.75.

IDEXX Laboratories Stock Up 2.2 %

IDXX opened at $415.30 on Friday. IDEXX Laboratories, Inc. has a twelve month low of $398.50 and a twelve month high of $548.88. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The company has a 50-day moving average price of $438.03 and a 200 day moving average price of $447.25. The company has a market cap of $33.78 billion, a PE ratio of 38.92, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39.

Insider Buying and Selling at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP George Fennell sold 9,986 shares of the stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares of the company’s stock, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their position. The disclosure for this sale can be found here. 2.18% of the stock is owned by insiders.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.